UFC and Aurora Cannabis announced a partnership in 2019 to investigate potential links between CBD, athletes’ wellbeing and recovery. It was a notable commercial and research initiative, but did not continue as originally planned: Aurora announced its termination in September 2020.
What was planned in 2019?

UFC’s announcement of 21 May 2019 described a multi-year global partnership intended to support hemp-derived CBD research, product development and education, focusing on athletes’ wellbeing and recovery.
The key word is “research”. Announcing the partnership did not establish that CBD’s recovery or pain-relieving effects had been proven in UFC athletes. An organisation’s commercial partnership is not a medical treatment recommendation.
The partnership ended the following year
In a stock-market announcement on 8 September 2020, Aurora said it and UFC had agreed to end the partnership. Aurora linked the decision to cost discipline and a changed business focus. The announcement also described a one-off termination payment and avoiding future costs.
It is therefore misleading to describe the 2019 initiative as an ongoing UFC–Aurora partnership. Its history shows interest in CBD, but the termination itself proves neither that CBD works nor that it does not.
Different types of CBD evidence matter
An athlete’s personal experience, a company’s product description and a controlled clinical trial carry different evidential weight. CBD does not generally cause THC-like intoxication, but that does not mean it has no biological effects or is safe for everyone.
We discuss the evidence and its limitations in our articles on cannabis and sport (in Estonian), and CBD and sleep (in Estonian).
